Abbvie, Genmab Blood-cancer Drug Has Competitive Profile

Dow Jones06-30

1413 GMT - AbbVie and Genmab's blood-cancer drug Epkinly showed a competitive profile in a late-stage lymphoma trial that boosts confidence in its potential, Bank of America analysts say in a research note. Strong results for a drug combination including Epkinly as a second-line treatment for diffuse large B-cell lymphoma support confidence in its potential to move to the first line of therapy, the analysts say. The study results can drive investor sentiment on Danish biotech company Genmab ahead of a busy second half, they add. Genmab is due to release data on two wholly-owned drugs--Rina-S in ovarian cancer and petosemtamab in head and neck cancer--that are expected to become core assets for the company, the analysts say. Each represents a $2 billion sales opportunity, according to Bank of America. Genmab shares rise 5.3%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

June 30, 2026 10:14 ET (14:14 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647554085?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 22:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647554085","market":"hk","top_or_hot":-1,"title":"Abbvie, Genmab Blood-cancer Drug Has Competitive Profile","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1413 GMT - AbbVie and Genmab's blood-cancer drug Epkinly showed a competitive profile in a late-stage lymphoma trial that boosts confidence in its potential, Bank of America analysts say in a research note. Strong results for a drug combination including Epkinly as a second-line treatment for diffuse large B-cell lymphoma support confidence in its potential to move to the first line of therapy, the analysts say. The study results can drive investor sentiment on Danish biotech company Genmab ahead of a busy second half, they add. Genmab is due to release data on two wholly-owned drugs--Rina-S in ovarian cancer and petosemtamab in head and neck cancer--that are expected to become core assets for the company, the analysts say. Each represents a $2 billion sales opportunity, according to Bank of America. Genmab shares rise 5.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 10:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbvie, Genmab Blood-cancer Drug Has Competitive Profile</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbvie, Genmab Blood-cancer Drug Has Competitive Profile\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 22:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1413 GMT - AbbVie and Genmab's blood-cancer drug Epkinly showed a competitive profile in a late-stage lymphoma trial that boosts confidence in its potential, Bank of America analysts say in a research note. Strong results for a drug combination including Epkinly as a second-line treatment for diffuse large B-cell lymphoma support confidence in its potential to move to the first line of therapy, the analysts say. The study results can drive investor sentiment on Danish biotech company Genmab ahead of a busy second half, they add. Genmab is due to release data on two wholly-owned drugs--Rina-S in ovarian cancer and petosemtamab in head and neck cancer--that are expected to become core assets for the company, the analysts say. Each represents a $2 billion sales opportunity, according to Bank of America. Genmab shares rise 5.3%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 10:14 ET (14:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABBV","symbol_name":"艾伯维公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647554085","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647554085","pubTimestamp":1782828840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1413 GMT - AbbVie and Genmab's blood-cancer drug Epkinly showed a competitive profile in a late-stage lymphoma trial that boosts confidence in its potential, Bank of America analysts say in a research note. Strong results for a drug combination including Epkinly as a second-line treatment for diffuse large B-cell lymphoma support confidence in its potential to move to the first line of therapy, the analysts say. The study results can drive investor sentiment on Danish biotech company Genmab ahead of a busy second half, they add. Genmab is due to release data on two wholly-owned drugs--Rina-S in ovarian cancer and petosemtamab in head and neck cancer--that are expected to become core assets for the company, the analysts say. Each represents a $2 billion sales opportunity, according to Bank of America. Genmab shares rise 5.3%.  Dow Jones NewswiresJune 30, 2026 10:14 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABBV":"艾伯维公司","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4207":"综合性银行","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4581":"高盛持仓","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4553":"喜马拉雅资本持仓","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE000WAW04H5.SGD":"RQI GLOBAL \"I\" (SGD) INC A","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","BK4566":"资本集团","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","IE000SO60NU8.SGD":"RQI GLOBAL \"I\" (SGDHDG) ACC A","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","GMAB":"Genmab A/S","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4550":"红杉资本持仓","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","BAC":"美国银行"},"translate_title":"艾伯维(Abbvie)、Genmab血癌药物具有竞争力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"GMAB":0.9,"BAC":0.68},"content_text":"1413 GMT - AbbVie and Genmab's blood-cancer drug Epkinly showed a competitive profile in a late-stage lymphoma trial that boosts confidence in its potential, Bank of America analysts say in a research note. Strong results for a drug combination including Epkinly as a second-line treatment for diffuse large B-cell lymphoma support confidence in its potential to move to the first line of therapy, the analysts say. The study results can drive investor sentiment on Danish biotech company Genmab ahead of a busy second half, they add. Genmab is due to release data on two wholly-owned drugs--Rina-S in ovarian cancer and petosemtamab in head and neck cancer--that are expected to become core assets for the company, the analysts say. Each represents a $2 billion sales opportunity, according to Bank of America. Genmab shares rise 5.3%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 30, 2026 10:14 ET (14:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647554085","isCrawlerRequest":true}